Cancer Prevention

New Advances in Cancer – A Discussion with Dr. Raza Bokhari, Medicus Pharma

 
Dr. Raza Bokhari the CEO of Medicus Pharma, a biotech/life sciences company focused on advancing the clinical development programs in the area of oncology joins eHealth Radio and the Cancer Information and Health News Channels. Today, he will discuss some significant progress in ongoing research that can pave the way for better treatment of skin and prostate cancers.
Listen to interview with host Eric Michaels & guest Dr. Raza Bokhari discuss the following:
Medicus Pharma has been making huge progress in cancer treatment most recently in the areas of prostate and skin cancer. You recently announced significant news with your new chemo cancer patch for a common skin cancer called Skinject. What have the results shown so far?
From what I understand, this type of cancer, basal cell carcinoma, is treated with invasive surgery, will the hope be that Skinject replaces the knife?
What lies ahead for Skinject? How much more trials would be needed and when can we see this available for patients?
Medicus has also been making advances in prostate cancer with a drug Medicus is developing. Give us more information about the drug and how does it address this common cancer in men?
What are the next steps for your prostate drug? Where can folks learn more about trial for that and Skinject?
Dr. Raza Bokhari – a physician turned serial entrepreneur - has a demonstrated successful track record in aggregating and accelerating life sciences, healthcare services and Pharmaceutical R&D companies.
He previously served as Executive Chairman and CEO of FSD Pharma (Nasdaq: HUGE), where his strategies successfully pivoted the company out of medicinal cannabis and into a clinical stage pharmaceutical R&D, a transition marked by a NASDAQ listing in January 2020, and raising nearly $100M institutional capital to fuel growth and expansion.
Dr. Bokhari has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, and an Executive MBA from Temple University, Fox School of Business & Management.
In addition to his corporate roles, Dr. Bokhari serves as the Vice Chairman of the World Affairs Council of Philadelphia. He formerly served on the Board of Temple University’s Fox School of Business and Management as Chairman of the Executive Advisory Committee and was a Trustee of the esteemed Franklin Institute and Foreign Policy Research Institute.
Dr. Bokhari, through his family foundation, believes in giving back and investing in the community. In recognition of a $1 million gift, he made to his alma mater, Temple University, its Fox Business School named the Innovation & Entrepreneurship Institute Suite in his honor. The school acknowledged Dr. Bokhari in 2018 by naming him a Centennial Honoree, a special collection of entrepreneurs, visionaries, and disruptors who helped shape the Fox School and the business world since 1918.
Website: https://medicuspharma.com
Social Media Links: Linkedin: https://www.linkedin.com/company/medicus-pharma-ltdX: https://x.com/MedicusLtd
People also listened to this: April Is Autism Month: Exploring Why Early Applied Behavior Analysis (ABA) Intervention is Critical in the First Five Years

The Hidden Health Risks Inside Our Homes

 
Ksenia Kolyeva, Senior Marketing Manager at Ecosense, a Silicon Valley–based company leading the way in smart radon detection and environmental health technology joins eHealth Radio and the Health News and Technology Channels.
Listen to interview with host Eric Michaels & guest Ksenia Kolyeva discuss the following:
A common headline is that radon is one of the overlooked health risks. Why is radon considered that way. Why should people pay attention to radon today?
What everyday habits or home conditions can increase the radon exposure? What steps can listeners take to lower the radon exposure risk?
When you know what is happening in the home environment beyond radon how does that help you be more proactive, about your health?
Technology evolves. I wonder how the EcoQube Flex changes the way the homeowners monitor the environmental health issues and the way the homeowners respond in time.
When getting a new home, where do I start? What type of resources (i.e., EcoQube Flex) will help reduce the feeling of being overwhelmed while supporting one on their path to their home?
If there’s one simple mindset shift or small action you’d encourage people to take when it comes to their indoor health, what would it be — and how can greater awareness of things like radon make a real difference over time?
About Ecosense
Ecosense, headquartered in Silicon Valley, is a global leader in smart radon detection and environmental health technology. The company’s patented ion chamber technology—validated by the University of Michigan and the Kansas State University Radon Chamber—delivers scientific-grade radon monitoring previously accessible only to industry professionals.
Ecosense’s award-winning products include EcoQube®, named to TIME’s Best Inventions of 2021, and EcoBlu™, featured by Reader’s Digest as a top home-improvement gift. Ecosense continues to redefine environmental sensing with intelligent, consumer-friendly solutions designed to protect families and improve indoor health.
Website: https://ecosense.io
Social Media Links: Facebook: https://www.facebook.com/ecosense.ioInstagram: https://www.instagram.com/ecosense.incX: https://x.com/ecosenseinc
People also listened to this: He Lived in His Car—Now He’s Transforming a Million Lives

The Role of AI in Empowering Patients and Improving Breast Cancer Detection

 
Dana Brown, President and CEO of iCAD, a  global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions joins eHealth Radio and the Cancer Prevention and Health News Channels.
Listen to interview with host Eric Michaels & guest Dana Brown discuss the following:
How is AI in transforming early breast cancer detection?
Why is personalized breast cancer risk assessment important?
How is AI-Powered screening becoming more accessible with ProFound Cloud?
What is the connection between Breast Arterial Calcification (BAC) and women’s heart health?
How does AI help empower patients and clinicians?
How is AI addressing health equity & expanding global access to services?
A 30-year technology industry veteran, Dana Brown is currently as President and CEO of iCAD. She previously served as Senior Vice President, Chief Strategy and Operations Officer at Susan G. Komen and Senior Vice President and Chief Digital Officer at United Way Worldwide. Ms. Brown was also a founding team member of multiple successful ventures including co-founder and CMO for MetaSolv Software, CEO of Ipsum Networks and spent the early years of her career at Texas Instruments and Arthur Andersen.
Website: https://www.icadmed.com
Social Media Links: Linkedin: https://www.linkedin.com/company/icadFacebook: https://www.facebook.com/icadmed
People also listened to this: How Specialists & General Providers Together Can Drive Early Detection of MASLD/MASH to Transform Patients’ Liver Health

Turning Tragedy into Action – A Family’s Fight for Genetic Awareness

 
Dr. Matt Goldstein, the CEO of jScreen, that focuses on providing accessible, life-saving genetic testing to empower individuals with critical health insights joins eHealth Radio and the Cancer Prevention and Health News Channels.
Listen to interview with host Eric Michaels & guest Dr. Matt Goldstein discuss the following:
Tell me about your role at jScreen and your background.
How did you come to join jScreen and tell us about the public initiative and what they do?
What is the most important thing people need to know about genetic testing when planning a family?
Jscreen also offers genetic cancer testing – can you tell us about this?
Where can people go to learn more about jScreen and get tested?
Summary: Genetic and Cancer genetic testing can save lives and the more people that do get tested the more lives can be saved.  To learn more visit https://www.jscreen.org.
Dr. Matt Goldstein is a dedicated physician-scientist and entrepreneur with a passion for advancing genetic research. As CEO of jScreen, he focuses on providing accessible, life-saving genetic testing to empower individuals with critical health insights.
With extensive experience in biotech, Dr. Goldstein has led major initiatives, including founding and guiding companies like Tango Therapeutics and Neon Therapeutics through pivotal clinical developments and strategic partnerships. A graduate of Stanford University's MD/PhD program, he completed his clinical training at Harvard Medical School.
Driven by both professional and personal experiences, including the loss of his eldest daughter, Havi, to Tay-Sachs disease, Dr. Goldstein is deeply committed to jScreen's mission of proactive health management.
Website: https://www.jscreen.org
Social Media Links: X: https://x.com/myjscreenInstagram: https://www.instagram.com/getjscreenedLinkedin: https://www.linkedin.com/company/jscreen
People also listened to this: Empowering Women to Navigate Perimenopause with Confidence

A Science-Based Pathway to Becoming a Super-Ager

 
Dr. Sharad P. Paul, MD, is a skin cancer specialist, family physician, evolutionary biologist, storyteller, social entrepreneur, and an adjunct professor at Auckland University of Technology joins eHealth Radio and the Cancer Information & Health News Channels. His new book is Biohacking Your Genes: 25 Laws for a Smarter, Healthier, and Longer Life.
Listen to interview with host Eric Michaels & guest Dr. Sharad P. Paul discuss the following:
What's the most surprising thing you found during your research for this book?
What role does nutrition play in your approach to wellness and longevity?
Do you advocate for any specific medications to live longer as some longevity clinics do?
How does your book address the topic of aging, and what do you mean by super-aging?
How do you see technology influencing our health and wellness practices today?
How has your personal journey as a physician shaped the content of your book?
Any quick practical tips from your book that readers can easily incorporate into their daily lives?
Sharad P. Paul, MD, is a skin cancer specialist, family physician, evolutionary biologist, storyteller, social entrepreneur, and an adjunct professor at Auckland University of Technology. Born in England, with a childhood in India, he’s a global citizen and a noted polymath. He received the Ko Awatea International Excellence Award for “leading health Improvement on a global scale, and his work towards patient-centered medicine across several countries.” He has authored works of fiction, non-fiction, poetry, and medical textbooks. His new book is Biohacking Your Genes: 25 Laws for a Smarter, Healthier, and Longer Life (Beyond Words Publishing, Oct. 14, 2024).
Website: https://drsharadpaul.com | https://biohackingyourgenes.com
Social Media Links: Facebook: https://www.facebook.com/skininyourgamemd  Instagram: https://www.instagram.com/skininyourgame  TikTok: https://www.tiktok.com/@skininyourgame 
People also listened to this: The Modern Facelift with Dr. Seify

New Innovations: Chemo Cargo Load Against Common Skin Cancer Moves Forward

 
Dr. Raza Bokhari, the CEO of Medicus Pharma, a biotech/life sciences company focused on accelerating the clinical development of SkinJect joins eHealth Radio and the Cancer Information and Health News Channels. This small skin patch delivers a cargo of chemo directly to a common form of skin cancer.
Listen to interview with host Eric Michaels guest Dr. Raza Bokhari discuss the following:
Could you tell me more about your background as a physician? And how did that experience help you originate Medicus?
Your area is treating basal cell carcinoma. Can you tell our audience more about this type of cancer and who gets it?
Can you explain how the Skinject patch works in simple terms? How does it treat skin cancer called basal cell carcinomas compared to more familiar treatments like surgery or creams?
Can you share some of the key benefits and outcomes you hope SkinJect patch will bring to patients with skin cancer? Could it potentially replace current treatments?
Where can patients learn more about Skinject and Medicus Pharma and information about ongoing clinical trials?
Raza Bokhari, MD, Executive Chairman & CEO of Medicus Pharma
A recipient of the Philadelphia Business Journal’s "40 under 40" award, Dr. Raza Bokhari—a physician turned serial entrepreneur—has a demonstrated track record of successfully aggregating and accelerating life sciences, healthcare services, and Pharmaceutical R&D companies.
Dr. Bokhari is the managing partner of RBx Capital, LP, and also serves as the Chairman of the Board of Parkway Clinical Laboratories (PCL), a fifty-year-old College of American Pathologist (CAP) accredited, CLIA-certified in-vitro diagnostic laboratory.
Dr. Bokhari has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, and an Executive MBA from Temple University, Fox School of Business & Management.
In addition to his corporate roles, Dr. Bokhari serves as the Vice Chairman of the World Affairs Council of Philadelphia. He formerly served on the Board of Temple University’s Fox School of Business and Management as Chairman of the Executive Advisory Committee and was a Trustee of the esteemed Franklin Institute and Foreign Policy Research Institute.
Dr. Bokhari, through his family foundation, believes in giving back and investing in the community. In recognition of a $1 million gift, he made to his alma mater, Temple University, its Fox Business School named the Innovation & Entrepreneurship Institute Suite in his honor.
Website: https://medicuspharma.com
Social Media Links: Linkedin: https://www.linkedin.com/company/medicus-pharma-ltdX: https://x.com/MedicusLtd
People also listened to this: SonarMD Keeps IBD Patients and Doctors Connected

Genetic and Genetic Cancer Screening Saves Lives

 
Karen Grinzaid, Assistant Professor of Human Genetics and Executive Director of JScreen, a national online genetic disease screening program based out of Emory University School of Medicine again joins eHealth Radio and the Health News and Technology Channels.
Listen to interview with host Eric Michaels and guest Karen Grinzaid discuss the following:
Tell us about jscreen.org – what you do and what kind of genetic diseases and genetic cancers do you test for?
Tell me first about genetic testing for cancer – are many cancers genetic and if you find you have one what are the options?
Tell us about testing for genetic diseases and again once you find out the information how to best use it?
How does one get tested – explain the process of how to get the test, and the results?
Please just summarize how important and easy it is go get genetic and cancer genetic screening?
Karen Grinzaid is Assistant Professor of Human Genetics and Executive Director of JScreen, a national online genetic disease screening program based out of Emory University School of Medicine. She has extensive experience in genetic counseling and testing, clinical care and clinical research. Karen is proud of JScreen’s success in helping couples across the U.S. have healthy babies and in giving people the information they need to help prevent the devastating effects of hereditary cancer.
Karen received her B.A. in Psychology from Northwestern University and her M.S. in Human Genetics from Sarah Lawrence College. She is certified in Genetic Counseling by the American Board of Medical Genetics/American Board of Genetic Counseling and as a Clinical Research Coordinator through the Association of Clinical Research Professionals.
About JScreen
JScreen is a national non-profit public health initiative dedicated to preventing genetic diseases and cancer common in Jewish and other populations. Headquartered in Atlanta at Emory University School of Medicine, the JScreen initiative provides convenient at-home access to cutting-edge genetic testing technology, patient education, and genetic counseling services. JScreen believes the combination of education, access to premier genetic screening technologies, and personalized, confidential support are the keys to preventing devastating diseases. 
 
 
Website: https://www.jscreen.org  
Social Media Links: Facebook: @MyJScreen Instagram: @GetJScreened Twitter: @MyJScreen
People also listened to this: Pelvic Floor Physical Therapy with Dr. Melanie Carminati

AI-powered technology enabling early detection of serious health diseases

 
 
Jim Kean, the CEO of Molecular You joins eHealth Radio and the Health News and Technology Channels to discuss how their AI-powered technology is enabling early detection of serious health diseases even before symptoms appear.
Listen to interview with host Eric Michaels and guest Jim Kean discuss the following:
What particular problems does Molecular You’s solution solve?
What inspired you to feel passionate about this cause?
How important is AI to what you do?
How do you think this will change the healthcare world?
What would you recommend to listeners who want to be more proactive about their long-term health today?
Jim Kean is the CEO of Molecular You. He is a senior technology executive with an innovative career focused on making healthcare easier by pioneering disruptive consumer-oriented health and wellness digital experiences. The consistent theme: creating user delight, loyalty, and retention while fundamentally re-engineering the cost of delivery.
As the former CEO of WellnessFx™, he provided affordable consumer health services, earning recognition as the 2012 Innovative Company of the Year. Kean also spearheaded online health communities as President of Sapient Health Network, which merged with WebMD in 1999. After WebMD, Jim served as Entrepreneur in Residence with Alloy Ventures of Palo Alto. With a rich history of scaling companies, he continues to lead groundbreaking ventures, most recently as CEO of Molecular You.
 
Website: https://www.molecularyou.com
People also listened to this: Making It Through Your First Holiday Season After a Divorce

Cell-ing the Future: CytoImmune’s CEO Talks About Expanded Role in Cell Therapy

 
Dr. Jose E Vidal who is currently the CEO of CytoImmune Therapeutics, a company at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials joins eHealth Radio and the Health News and Cancer Information Channels.
Listen to interview with host Eric Michaels and guest Dr. Jose E. Vidal discuss the following:
What is gene and cell therapy and how does it work?
What conditions can be treated with cell therapy?
What is the difference between treatment therapy and curative therapy?
What is the difference between chemo/radio therapy and immunotherapy for cancer?
When will cell therapy be available to patients? What are the limitations?
In conclusion, cell therapy is the next significant step in fighting hard to treat cancer and autoimmune conditions. It has been proven to provide results superior to any treatment seen before. Now, we are working on improving access for patients by optimizing the manufacturing process and lowering therapy cost.
Dr. Jose Eduardo Vidal obtained his doctoral degree in Cellular and Molecular Biology from the University of Puerto Rico. He started his career in the pharmaceutical industry in Wyeth as a process development scientist working with small molecules and the first Biologics development pipeline upon the acquisition of Immunex.
With Wyeth he worked on the development and commercial launch of Mylotarg (very first ADC). He continued to develop as a biopharmaceutical professional occupying positions of increased responsibility in Tech Services, Process Development and Quality. After 10 years with the company and managing 14 sites world wide Jose joined Amgen as the head of Process Development. With Amgen Jose managed the biologics new product development with over one hundred programs in the pipeline. Jose also managed the drug substance manufacturing organization as the VP of operations and also lead the global late stage product pipeline as the global VP of Process Development where he got acquainted with Cell and Gene therapy.
In 2018 Jose joined Atara where he led the company as SVP of Process Development and Global Quality to develop and submit for commercial licensing the first ever Allogeneic TCell therapy product (Ebvallo) which was approved for commercial distribution in Dec 2022. He also successfully designed and led the development of TCell therapy manufacturing process in stirred tank, perfusion bioreactors.
Lately Jose joined Cytoimmune Therapeutics as the Chief Operations Officer and has been working in starting up the company and the operation from the ground up with operations in PR. Cytoimmune is focused in developing oncology and autoimmune malignancies therapies based on Allogeneic NK-CAR cells.
Jose has also worked with other operations and startups as Pfizer and Biovail and has served as advisor for multiple biotechnology startups with 25 years in the industry in which he has achieved taking from RnD to market more than 200 products/therapies and has pioneered the evolution of therapies from chemical synthesis, biologics to cell and gene therapy. Jose is an early adopter and champion of real time predictive statistical modeling and deep machine learning.
Website: https://www.cytoimmune.com
Social Media Links: Linkedin: https://www.linkedin.com/company/cytoimmune-therapeutics  Twitter: @CytoImmune
People also listened to this: A Breakthrough Solution for Treating Central Nervous System Disorders Including Strokes and Cluster Headaches

Targeted Radiotherapies for Patients with Unmet Needs: A Conversation with Actinium Pharmaceuticals CEO Sandesh Seth

 
 
Sandesh Seth, CEO of Actinium Pharmaceuticals which is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Sandesh Seth discuss the following:
What is unique about Actinium’s radiotherapy approach?
Tell me about Iomab-B, its target population, and how it will affect the patient journey.
Actimab-A is also in AML. How is it different from Iomab-B and what’s the approach here?
What’s next in your pipeline?
Tell me what upcoming catalysts I should expect in the second half of 2023.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and several internal programs in solid tumors. Actinium holds more than 200 patents and patent applications.
Website: https://www.actiniumpharma.com
Social Media Links: Linkedin: https://linkedin.com/company/actinium-pharmaceuticals-inc-Facebook: https://facebook.com/people/Actinium-Pharmaceuticals-IncTwitter: https://twitter.com/ActiniumPharma
People also listened to this: The Miracle of Enzymes to Heal Digestive Problems